Aims: To investigate the differences in insulin resistance between women with recurrent miscarriage and those with normal pregnancy. Methods: Pregnant women with a history of recurrent miscarriage were included in the patient group (n = 97), while those with no history of abnormal pregnancy were included in the control group (n = 52). Both groups consented to undertake an oral glucose tolerance test and insulin-releasing test between the 5th and 13th weeks of pregnancy. Results: (1) Levels of fasting plasma glucose, fasting plasma insulin, homeostasis model assessment of insulin resistance index, and homeostasis model assessment β function were not statistically significantly different (p < 0.05) between the two groups. (2) The area under the curve of glucose and area under the curve of insulin were higher in the patient group than in the control group. The composite insulin sensitivity index of the patient group was lower than that of the control group. The differences in these three parameters between the groups were statistically significant (p < 0.05). Conclusion: Women with a history of recurrent miscarriage are at an increased risk for insulin resistance during the first trimester of a new pregnancy.

1.
Porter TF, Scott JR: Evidence-based care of recurrent miscarriage. J Clin Obstet Gynecol 2005;19:85–101.
2.
Stephenson M, Kutteh W: Evaluation and management of recurrent early pregnancy loss. J Clin Obstet Gynecol 2007;50:132–145.
3.
ZheYi Cao: Chinese Obstetrics and Gynecology, ed 2. Beijing, People’s Medical Publishing House, 2004, p 2453.
4.
Homburg R: Pregnancy complications in PCOS. J Clin Endocrinol Metab 2006;20:281–292.
5.
Jauniaux E, Farquharson RG, Christiansen OB, et al: Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006;21:2216–2222.
6.
Practice Committee of the American Society for Reproductive Medicine: Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008;90:S60.
7.
Craig LB, Ke RW, Kutteh WH: Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002;78:487–490.
8.
Li T, Huan S, Qun L, et al: Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. J Clin Endocrin Metab 2007;92:1430–1433.
9.
Diejomaoh M, Jirous J, Azemi M, et al: Insulin resistance in women with recurrent spontaneous miscarriage of unknown aetiology. J Med Princ Pract 2007;16:114–118.
10.
Li X: Metabolic Syndrome. Insulin Insistence Syndrome, ed 2. Beijing, People’s Medical Publishing House, 2007, pp 91–98.
11.
Matsuda M, DeFronzo RA: Insulin sensitivity index obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–1470.
12.
Li H, Gong Y, Jia W, et al: The accuracy of three simple insulin sensitivity indices in patients with impaired glucose tolerance. Chin J Hypertens 2004;12:204–206.
13.
Nawaz FH, Khalid R, Naru T, et al: Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? J Obstet Gynaecol Res 2008;34:832–837.
14.
Zolghadri J, Tavana Z, Kazerooni T, et al: Relationship between abnormal glucose tolerance test and history of previous recurrent miscarriages, and beneficial effect of metformin in these patients: a prospective clinical study. Fertil Steril 2008;90:727–730.
15.
Khattab S, Mohsen IA, Foutouh IA, et al: Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol 2006;22:680–684.
16.
Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:524–529.
17.
Jakubowicz DJ, Essah PA, Seppala M, et al: Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. J Clin Endocrinol Metab 2004;89:833–839.
18.
Glueck CJ, Sieve L, Zhu B, et al: Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor-1 gene and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006;55:345–352.
19.
Moll E, Bossuyt PM, Korevaar JC, et al: Effect of clomiphene citrate plus metformin and clomiphene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double-blind clinical trial. BMJ 2006;332:1485.
20.
Legro RS, Barnhart HX, Schlaff WD, et al: Clomiphene, metformin or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551–566.
21.
Palomba S, Pasquali R, Orio F Jr, et al: Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome: a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol 2009;70:311–321.
22.
Palomba S, Falbo A, Orio F Jr, et al: Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2009;92:1646–1658.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.